Pooled analyses of overall survival shows the addition of CDK inhibitors to fulvestrant confers a consistent survival benefit in patients with breast cancer. Read More ›

As mutation-associated targeted therapies are identified, it is critical to address genetic testing disparities. Read More ›

CDK4/6 inhibitors have similar efficacy; therefore, clinicians should consider toxicity when selecting an optimal therapeutic approach. Read More ›

Use of chemotherapy near the end of life in patients with metastatic breast cancer may potentially negatively impact quality of life. Read More ›

Low-dose tamoxifen could be used for prevention and to increase sensitivity of mammograms in premenopausal women. Read More ›

Researchers report on early results from an effort to develop a predictive model and targeted strategies for communication and intervention for cancer screening during the COVID-19 pandemic. Read More ›

Based on current drug pricing strategies in the United States, ribociclib combination therapy is unlikely to be cost-effective for treating postmenopausal patients with HR-positive HER2-negative advanced breast cancer. Read More ›

Read More ›

For patients with recurrent metastatic HER2-positive breast cancer, new therapies such as margetuximab will expand treatment options. Read More ›

To help inform treatment decision-making, guidelines have been developed on surveillance mammography for early breast cancer survivors who are ≥75 years of age. Read More ›